Syndicate content The Healthcare Sales & Marketing Network
Healthcare Sales & Marketing Network NewsFeed
Updated: 8 min 27 sec ago

Eigen USA and Hitachi Medical Systems Europe Switzerland Announce a Collaborative Agreement for Hitachi to Distribute the Artemis, Eigen's Robotic 3D Targeted Prostate Biopsy Device

Fri, 03/11/2016 - 13:43
The combined Hitachi Noblus and Artemis Eigen systems will be showcased at the European Association of Urology annual meeting in Munich, March 12th-14th, 2016, Booth #E16 ZUG, Switzerland, March 11, 2016 -- (Healthcare Sales & Marketing Network) -- Eig...
Devices, Oncology, Distribution
Hitachi Medical Systems, Artemis, Eigen, prostate biopsy

MedCom GmbH and Hitachi Medical Systems Europe Announce an Agreement to Distribute BiopSee(R), MedCom's Fusion Imaging System for Stereotactic, Navigated, Targeted Prostate Biopsy and Therapy Guidance, for use in Conjunction With Hitachi Ultrasound System

Fri, 03/11/2016 - 13:34
The combined Hitachi Noblus and MedCom BiopSee® systems will be showcased at the European Association of Urology (EAU) annual meeting in Munich, March 12th-14th, 2016, Booth #E16 ZUG, Switzerland, March 11, 2016 -- (Healthcare Sales & Marketing Netw...
Devices, Radiology, Oncology, Distribution
Hitachi Medical Systems, MedCom GmbH, BiopSee, prostate biopsy

HeartStitch, Inc. Appoints Renowned Cardiac Surgeon to Its Clinical Advisory Board

Fri, 03/11/2016 - 13:27
Dr. Yuriy Pya, Chief of Cardiac Surgery at the National Research Center for Cardiac Surgery, Kazakhstan's Top Cardiac Hospital, Joins HeartStitch(R) Clinical Advisory Board FOUNTAIN VALLEY, CA--(Healthcare Sales & Marketing Network) - HeartStitch®t...
Devices, Cardiology, Surgery, Personnel
HeartStitch, NobleStitch, vascular suture

Regeneron and Sanofi Announce Topline Results of Phase 3 Monotherapy Study Demonstrating Superiority of Sarilumab vs. Adalimumab in Patients with Active Rheumatoid Arthritis

Fri, 03/11/2016 - 13:13
TARRYTOWN, N.Y. and PARIS, March 11, 2016 -- (Healthcare Sales & Marketing Network) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that a Phase 3 monotherapy study met its primary endpoint demonstrating that sarilumab was sup...
Biopharmaceuticals
Regeneron Pharmaceuticals, Sanofi, sarilumab, rheumatoid arthritis

Revolutionary 3D Cardiac Mapping System Developed by Aurora Health Care Physician Receives FDA Clearance

Thu, 03/10/2016 - 14:58
MILWAUKEE, WI--(Healthcare Sales & Marketing Network) - Dr. Jasbir Sra, an internationally recognized cardiac electrophysiologist with Aurora Health Care, has received clearance from the Food and Drug Administration (FDA) to market a new three-dimensional ...
Devices, Cardiology, Radiology, FDA
Aurora Health Care, Navik 3D, cardiac mapping, atrial fibrillation

ProMark(R) Prostate Cancer Prognostic Now Included in NCCN Guidelines

Thu, 03/10/2016 - 14:51
Metamark continues to advocate for broader adoption of precision medicine in prostate cancer care CAMBRIDGE, Mass., March 10, 2016 -- (Healthcare Sales & Marketing Network) -- Metamark Genetics, Inc., ("Metamark" or the "Company"), ...
Diagnostics, Oncology
Metamark Genetics, ProMark, prostate cancer, NCCN

Allergan Receives Complete Response Letter from FDA for Prior Approval Supplement for RESTASIS(R) (Cyclosporine Ophthalmic Emulsion) 0.05% Multi-Dose Preservative-Free Bottle

Thu, 03/10/2016 - 14:48
DUBLIN, March 10, 2016 -- (Healthcare Sales & Marketing Network) -- Allergan plc (AGN) announced today it has received a Complete Response Letter from the U.S. Food and Drug Administration (FDA) for its Prior Approval Supplement (PAS) for RESTASIS® (C...
Biopharmaceuticals, Ophthalmology, FDA
Allergan, RESTASIS, Cyclosporine, Chronic Dry Eye

Therabron Therapeutics Expands Management Team

Wed, 03/09/2016 - 15:06
ROCKVILLE, Md., March 9, 2016 -- (Healthcare Sales & Marketing Network) -- Therabron Therapeutics, Inc., a clinical-stage biotechnology company dedicated to advancing a new standard in respiratory care, today announced senior management team appointments....
Biopharmaceuticals, Personnel
Therabron Therapeutics, secretoglobin

Valeant Pharmaceuticals Announces The Addition Of Three New Independent Directors To Its Board

Wed, 03/09/2016 - 15:04
LAVAL, Quebec, March 9, 2016 -- (Healthcare Sales & Marketing Network) -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX) today announced that Dr. Fred Eshelman, Mr. Stephen Fraidin and Mr. Thomas W. Ross, Sr. have joined its Board of...
Biopharmaceuticals, Dermatology, Personnel
Valeant Pharmaceuticals

New "See-and-Treat" Truclear(TM) Hysteroscope Improves Options for Office Hysteroscopy

Wed, 03/09/2016 - 15:01
LONDON, March 9, 2016 -- (Healthcare Sales & Marketing Network) -- Smith & Nephew (NYSE: SNN; LSE: SN), the global medical technology business, today announced the launch of the TRUCLEAR 5C Hysteroscope Set for the combined diagnosis and removal of abnorm...
Devices, Product Launch
Smith & Nephew, TRUCLEAR, Hysteroscope

BME Launches The New Elite(R) Nitinol Bone Fixation System - Transcending Traditional Fixation

Wed, 03/09/2016 - 14:58
SAN ANTONIO, March 9, 2016 -- (Healthcare Sales & Marketing Network) -- BioMedical Enterprises, Inc. (BME), the leader in Nitinol fixation technology, announced today the launch of the new BME Elite® Nitinol Bone Fixation System. Working closely with ...
Devices, Orthopaedic, Product Launch
BioMedical Enterprises, BME Elite, Nitinol, Bone Fixation

NuVasive Announces Regulatory Approval of Reline(TM) Posterior Fixation Technology in Japan

Wed, 03/09/2016 - 14:49
Largest and Fastest Growing International Market Readies for Introduction of iGA(TM) Platform to Address Spinal Alignment and Drive Improved Long-Term Patient Outcomes SAN DIEGO, CA--(Healthcare Sales & Marketing Network) - NuVasive, Inc. (NUVA), a lea...
Devices, Orthopaedic, Neurosurgery, Regulatory
NuVasive, Posterior Fixation, Integrated Global Alignment

Karolinska Development's Portfolio Company Aprea Raises SEK 437 Million

Wed, 03/09/2016 - 14:45
STOCKHOLM, March 9, 2016 -- (Healthcare Sales & Marketing Network) -- Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces that its portfolio company Aprea AB has successfully raised SEK 437 million ($51 million) in a Series B financing roun...
Biopharmaceuticals, Oncology, Venture Capital
Aprea AB, Karolinska Development, p53

Contact us     New York    l    Miami    l    Sao Paulo     l    Mexico DF    l    London    l    Hong Kong